Isolated hepatic perfusion: Experimental evidence and clinical utility

Surgical Clinics of North America

Volumn 84, Issue 2, 2004, Pages 627-641

  De Wilt, Johannes H W ^a   Van Etten, Boudewijn ^a   Verhoef, Cornelis ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CISPLATIN; FLUOROURACIL; MELPHALAN; MITOMYCIN C; RECOMBINANT DNA; TUMOR NECROSIS FACTOR;

CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; HUMAN; HYPERTHERMIA; ISOLATED LIVER; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FLUOROURACIL; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MELPHALAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642381832     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00233-0     Document Type: Review

References (70)

1. Alexander H.R., Allegra C.J., Lawrence T.S. Treatment of metastatic cancer. Metastatic cancer to the liver. De Vita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 6th edition:2001;2690-2713 Lippincott Williams & Wilkins, Philadelphia (PA).
2. Welch J.P., Donaldson G.A. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 189:1979;496-502.
3. Sasson A.R., Sigurdson E.R. Surgical treatment of liver metastases. Sem Oncol. 29:2002;107-118.
4. Kemeny N., Kata F. Hepatic-arterial chemotherapy. Lancet Oncol. 2:(7):2001;418-428.
5. Schmoll H.J. The role of oxaliplatin in the treatment of advanced metastastic colorectal cancer: prospects and future directions. Sem Oncol. 29:(Suppl 5):2002;34-39.
6. Sulivan K.L. Hepatic artery chemoembolization. Sem Oncol. 29:2002;145-151.
7. Giovannini M. Percutaneous alcohol ablation of liver metastasis. Sem Oncol. 29:2002;192-195.
8. IJzermans J.N., van der Schelling G.P., Scheringa M., et al. Local treatment of liver metastases with recombinant tumor necrosis factor (rTNF): a phase one study. Neth J Surg. 43:1991;121-125.
9. Bartsch H.H., Pfizenmaier K., Schroeder M., et al. Intralesional application of recombinant tumor necrosis factor alphal induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol. 25:1989;287-291.
10. Curley S.A., Izzo F., Delrio P., et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 230:(1):1999;1-8.
11. Poon R.T., Fan S.T., Tsang F.H., et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 235:(4):2002;466-486.
12. Daly J.M., Kemeny N., Sigurdson E., et al. Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg. 122:1987;1273-1277.
13. Sterchi J.M. Hepatic artery infusion for metastatic neoplastic disease. Surgery, Gynecology & Obstetrics. 160:1985;477-489.
14. Ausman R.K. Development of a technique for isolated perfusion of the liver. NY State J Med. 61:1961;3393-3397.
15. Christoforidis D., Martinet O., Lejeune F.J., et al. Isolated liver perfusion for non-resectable liver tumours: a review. Eur J Surg Oncol. 28:(8):2002;875-890.
16. Jablonski P., Douglas M.C., Gordon E., et al. Studies on the isolated perfused pig liver. Br J Surg. 58:1971;129-137.
17. Skibba J., Condon R. Hyperthermic isolation-perfusion in vivo of the canine liver. Cancer. 51:1983;1303-1309.
18. Sindelar W.F. Isolation-perfusion of the liver with 5-fluorouracil. Ann Surg. 201:1985;337-343.
19. van de Velde C.J., Kothuis B.J., Barenbrug H.W., et al. A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res. 41:1986;593-599.
20. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 10:1992;52-60.
21. Eggermont A.M.M., Liénard D., Schraffordt Koops H., et al. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-a in combination with gamma-Interferon and melphalan. Fiers W., Buurman W.A. Tumor necrosis factor: molecular and cellular biology and clinical relevance. 1993;239-243 Karger Verlag, Basel (Switzerland).
22. Eggermont A.M.M., Schraffordt Koops H., Liénard D., et al. Isolated limb perfusion with high dose tumor necrosis factor-α in combination with IFNγ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 14:1996;2653-2665.
23. Eggermont A.M.M., Schraffordt Koops H., Klausner J., et al. Isolated limb perfusion with tumor necrosis factor-α and melphalan in 186 patients with locally advanced extremity sarcomas: the cumulative multicenter european experience. Ann Surg. 224:1996;756-765.
24. Borel Rinkes I.H.M., de Vries M.R., Jonker A.M., et al. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer. 75:1997;1447-1453.
25. Lang H., Thyen A., Nadalin S., et al. Isolated hyperthermic liver perfusion with high dose tumor necrosis factor alpha in pigs: an experimental study in preparation of clinical use. Eur Surg Res. 32:2000;1-10.
26. de Brauw L.M., van de Velde C.J., Tjaden U.R., et al. In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res. 44:1988;137-145.
27. de Brauw L.M., Marinelli A., van de Velde C.J., et al. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res. 51:1991;1694-1700.
28. Marinelli A., van de Velde C.J., Kuppen P.J., et al. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer. 62:1990;891-896.
29. Marinelli A., Pons D.H., Vreeken J.A., et al. High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats. Cancer Chemother Pharmacol. 28:1991;109-114.
30. Marinelli A., Dijkstra F.R., van Dierendonck J.H., et al. Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. Br J Cancer. 64:1991;74-78.
31. Marinelli A., van Dierendonck J.H., van Brakel G.M., et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer. 64:1991;1069-1075.
32. Radnell M., Jeppsson B., Bengmark S. A technique for isolated liver perfusion in the rat with survival and results of cytotoxic drug perfusion on liver tumor growth. J Surg Res. 49:1990;394-399.
33. Gnant M.F., Noll L.A., Terrill R.E., et al. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery. 126:1999;890-899.
34. van IJken M.G., van Etten B., de Wilt J.H., et al. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother. 23:2000;449-455.
35. de Wilt J.H., Manusama E.R., van Tiel S.T., et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 80:1999;161-166.
36. van der Veen A.H., de Wilt J.H., Eggermont A.M., et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer. 82:2000;973-980.
37. de Wilt J.H., ten Hagen T.L., de Boeck G., et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 82:2000;1000-1003.
38. van Etten B., de Vries M.R., van IJken M.G., et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer. 88:(2):2003;314-319.
39. Nakamoto T., Inagawa H., Takagi K., et al. Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model. Anticancer Res. 20:2000;619-622.
40. Nakamoto T., Inagawa H., Nishizawa T., et al. Antitumor effects of isolated hypoxic hepatic perfusion (IHHP) with high-dose TNF against colonic liver metastases in a rat model. Anticancer Res. 22:2002;2455-2459.
41. Rothbarth J., Sparidans R.W., Beijnen J.H., et al. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. J Pharmacol Exp Ther. 303:(2):2002;736-740.
42. Milas M., Feig B., Yu D., et al. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res. 3:1997;2197-2203.
43. de Roos W.K., de Wilt J.H.W., van der Kaaden M.E., et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg. 232:2000;814-821.
44. van Etten B., ten Hagen T.L., de Vries M.R., et al. Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. Br J Cancer. 86:(3):2002;436-442.
45. Sigurdson E.R., Ridge J.A., Kemeny N., et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 5:1987;1836-1840.
46. Archer S.G., Gray B.N. Vascularization of small liver metastases. Br J Surg. 76:1989;545-548.
47. Skibba J.L., Quebbeman E.J. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg. 121:1986;1266-1271.
48. Schwemmle K., Link K.H., Rieck B. Rationale and indications for perfusions in liver tumors: current data. World J Surg. 11:1987;99-120.
49. Aigner K.R., Walther H., Tonn J.C., et al. Isolated liver perfusion in advanced metastases of colorectal cancers. Onkologie. 7:1984;13-21.
50. Oldhafer K.J., Lang H., Frerker M., et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 123:1998;622-631.
51. Marinelli A., de Brauw L.M., Beerman H., et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal metastases confined to the liver. Jpn J Clin Oncol. 26:1996;341-350.
52. Hafstrom L.R., Holmberg S.B., Naredi P.L., et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 3:(2):1994;103-108.
53. Vahrmeijer A.L., van Dierendonck J.H., Keizer H.J., et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 82:(9):2000;1539-1546.
54. Fraker D.L., Alexander H.R., Thom A.K. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock. 44:1994;45-50.
55. Alexander H.R., Libutti S.K., Bartlett D.L., et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 6:2000;3062-3070.
56. de Vries M.R., Borel Rinkes I.H.M., van de Velde C.J., et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 147:1998;107-119.
57. Libutti S.K., Barlett D.L., Fraker D.L., et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 191:2000;519-530.
58. Alexander H.R., Bartlett D.L., Libutti S.K., et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 16:1998;1479-1489.
59. Alexander H.R., Brown C.K., Bartlett D.L., et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res. 4:1998;2357-2362.
60. Alexander H.R. Jr., Bartlett D.L., Libutti S.K. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 5:(5):2000;416-424.
61. Lindner P., Fjalling M., Hafstrom L., et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol. 25:1999;179-185.
62. Bartlett D.L., Libutti S.K., Figg W.D., et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 129:2001;176-187.
63. de Vries M.R., Borel Rinkes I.H.M., Swaak A.J., et al. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. Eur J Clin Invest. 29:1999;553-560.
64. Lans T.E., Bartlett D.L., Libutti S.K., et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res. 7:2001;784-790.
65. Savier E., Azoulay D., Huguet E., et al. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg. 138:(3):2003;325-332.
66. Eggermont A.M.M., van IJken M.G., van Etten B., et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 47:2000;776-781.
67. Ku Y., Tominaga M., Iwasaki T., et al. Efficacy of repeated percutaneous isoltaed liver chemoperfusion in local control of unresectavle hepatocellular carcinoma. Hepatogastroenterology. 45:1998;1961-1965.
68. van IJken M.G., de Bruijn E.A., de Boeck G., et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg. 228:1998;228763-228770.
69. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1971;1182-1186.
70. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.